Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9081563rdf:typepubmed:Citationlld:pubmed
pubmed-article:9081563lifeskim:mentionsumls-concept:C0013227lld:lifeskim
pubmed-article:9081563lifeskim:mentionsumls-concept:C0681842lld:lifeskim
pubmed-article:9081563lifeskim:mentionsumls-concept:C1323365lld:lifeskim
pubmed-article:9081563lifeskim:mentionsumls-concept:C0205464lld:lifeskim
pubmed-article:9081563lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:9081563lifeskim:mentionsumls-concept:C0597884lld:lifeskim
pubmed-article:9081563pubmed:issue2lld:pubmed
pubmed-article:9081563pubmed:dateCreated1997-4-3lld:pubmed
pubmed-article:9081563pubmed:abstractTextTritiated haloperidol and tritiated dopamine label postsynaptic dopamine receptors in mammalian brain. Clinical potencies of butyrophenones, phenothiazines, and related drugs correlate closely with their ability to inhibit tritiated haloperidol binding. These binding methods provide a simple in vitro means for evaluating new drugs as potential antischizophrenic agents.lld:pubmed
pubmed-article:9081563pubmed:languageenglld:pubmed
pubmed-article:9081563pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9081563pubmed:citationSubsetIMlld:pubmed
pubmed-article:9081563pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9081563pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9081563pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9081563pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9081563pubmed:statusMEDLINElld:pubmed
pubmed-article:9081563pubmed:issn0895-0172lld:pubmed
pubmed-article:9081563pubmed:authorpubmed-author:SnyderS HSHlld:pubmed
pubmed-article:9081563pubmed:authorpubmed-author:CreeseIIlld:pubmed
pubmed-article:9081563pubmed:authorpubmed-author:BurtD RDRlld:pubmed
pubmed-article:9081563pubmed:issnTypePrintlld:pubmed
pubmed-article:9081563pubmed:volume8lld:pubmed
pubmed-article:9081563pubmed:ownerNLMlld:pubmed
pubmed-article:9081563pubmed:authorsCompleteYlld:pubmed
pubmed-article:9081563pubmed:pagination223-6lld:pubmed
pubmed-article:9081563pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:9081563pubmed:meshHeadingpubmed-meshheading:9081563-...lld:pubmed
pubmed-article:9081563pubmed:meshHeadingpubmed-meshheading:9081563-...lld:pubmed
pubmed-article:9081563pubmed:meshHeadingpubmed-meshheading:9081563-...lld:pubmed
pubmed-article:9081563pubmed:meshHeadingpubmed-meshheading:9081563-...lld:pubmed
pubmed-article:9081563pubmed:meshHeadingpubmed-meshheading:9081563-...lld:pubmed
pubmed-article:9081563pubmed:meshHeadingpubmed-meshheading:9081563-...lld:pubmed
pubmed-article:9081563pubmed:meshHeadingpubmed-meshheading:9081563-...lld:pubmed
pubmed-article:9081563pubmed:meshHeadingpubmed-meshheading:9081563-...lld:pubmed
pubmed-article:9081563pubmed:meshHeadingpubmed-meshheading:9081563-...lld:pubmed
pubmed-article:9081563pubmed:year1996lld:pubmed
pubmed-article:9081563pubmed:articleTitleDopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.lld:pubmed
pubmed-article:9081563pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9081563lld:pubmed